5,079 Shares in Tempus AI, Inc. (NASDAQ:TEM) Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 5,079 shares of the company’s stock, valued at approximately $178,000.

Several other institutional investors have also modified their holdings of the company. James J. Burns & Company LLC acquired a new stake in shares of Tempus AI in the fourth quarter valued at $236,000. abrdn plc acquired a new position in Tempus AI in the 4th quarter worth about $2,784,000. Renaissance Capital LLC increased its position in Tempus AI by 121.3% in the 4th quarter. Renaissance Capital LLC now owns 24,757 shares of the company’s stock worth $836,000 after purchasing an additional 13,569 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Tempus AI during the 4th quarter worth about $1,091,000. Finally, Exchange Traded Concepts LLC boosted its stake in Tempus AI by 37.8% during the 4th quarter. Exchange Traded Concepts LLC now owns 84,174 shares of the company’s stock valued at $2,842,000 after purchasing an additional 23,070 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 51,504 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.39, for a total value of $2,183,254.56. Following the sale, the executive vice president now owns 246,085 shares of the company’s stock, valued at approximately $10,431,543.15. This trade represents a 17.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Eric P. Lefkofsky sold 476,209 shares of the firm’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $49.84, for a total value of $23,734,256.56. Following the completion of the sale, the chief executive officer now directly owns 6,502,643 shares in the company, valued at approximately $324,091,727.12. This represents a 6.82 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 2,229,449 shares of company stock worth $102,293,124 over the last 90 days.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on TEM. TD Cowen restated a “buy” rating and set a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Needham & Company LLC restated a “buy” rating and set a $56.00 target price on shares of Tempus AI in a research report on Tuesday, January 14th. Bank of America lifted their price objective on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research report on Friday, December 13th. William Blair downgraded Tempus AI from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Finally, Guggenheim initiated coverage on Tempus AI in a research note on Monday, December 9th. They set a “buy” rating and a $74.00 price objective for the company. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $58.55.

Tempus AI Stock Performance

NASDAQ:TEM opened at $83.75 on Friday. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The stock’s 50 day moving average price is $45.82 and its two-hundred day moving average price is $49.97. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $86.00.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.